N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • ClinicalTrials.gov ID: NCT07557251

Registry updated: 2026-08-31
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This early phase (Phase 1) study will evaluate BRII 5395, administered in combination with two approved anticancer agents, sintilimab and bevacizumab, in patients with advanced liver cancer caused by chronic hepatitis B virus (HBV) infection. The primary objective of the study is to assess the safety and tolerability of the combination therapy, as well as to explore preliminary evidence of clinical benefit.

Interventions

  • BRII-5395 (Drug)
    BRII-5395 will be given via IM injection
  • Sintilimab (Drug)
    Sintilimab will be given via IV infusion
  • Bevacizumab (Drug)
    Bevacizumab will be given via IV infusion

Eligibility criteria

Inclusion Criteria: 1. Diagnosis of locally advanced or metastatic HCC that is deemed unsuitable for surgical resection or transplant. 2. BCLC stages Intermediate (B) or Advanced (C). 3. Failed at least first-line systemic therapy, including ICIs; and disease is not amenable to curative surgical and/or locoregional therapies. 4. Adequate bone marrow and organ function status. 5. Life expectancy \> 3 months. 6. HBsAg \> 0.05 IU/mL at screening. Exclusion Criteria: 1. Any systemic anticancer therapy within specified period prior to the first dose of study treatment. 2. Any localized anticancer therapy within specified period prior to the first dose of study treatment. 3. History of anaphylactic hypersensitivity prior to the first dose of study treatment. 4. Known hypersensitivity to polyethylene glycol or any component of sintilimab or bevacizumab formulation, or any contraindications to sintilimab or bevacizumab. 5. Presence of cancer or metastasis in the central nervous system with clinical symptoms. 6. Remaining ≥ NCI-CTCAE grade 2 toxicities from previous anticancer therapy, unless otherwise specified. 7. Current or past history of infection with HIV, HCV, or active tuberculosis.

Conditions

Advanced HBV-Related Hepatocellular Carcinoma

Locations

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences — Beijing, China
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record